Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voluven versus human albumin for intraoperative volume replacement in pediatric open-heart surgery
2008-006749-18Phase 4Completed
- Sponsor
- Fresenius Kabi
- Start
- Dec 2008
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of Volulyte and albumin (human) in Cardiovascular Malformation (CVM) (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Primary efficacy endpoint. Started Dec 2008; status: completed.
02
Drugs
Volulytealbumin (human)
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2008-006749-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006749-18.